scispace - formally typeset
D

Dan Wang

Researcher at University of Massachusetts Medical School

Publications -  55
Citations -  3069

Dan Wang is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Genome editing & Gene delivery. The author has an hindex of 20, co-authored 49 publications receiving 1857 citations. Previous affiliations of Dan Wang include University of Massachusetts Amherst & University of Alabama at Birmingham.

Papers
More filters
Journal ArticleDOI

Adeno-associated virus vector as a platform for gene therapy delivery

TL;DR: The fundamentals of AAV and vectorology are discussed, focusing on current therapeutic strategies, clinical progress and ongoing challenges.
Journal ArticleDOI

Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses.

TL;DR: In this article, the authors used an Ad vector to deliver a Streptococcus pyogenes-derived Cas9 system (SpCas9) targeting Pten, a gene involved in NASH and a negative regulator of the PI3K-AKT pathway.
Journal ArticleDOI

CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.

TL;DR: CRISPR-based strategies to improve human health, with an emphasis on the delivery of CRISPR therapeutics directly into the human body using adeno-associated virus (AAV) vectors are described.
Journal ArticleDOI

AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy

TL;DR: It is shown that long-term parenteral administration of superphysiological doses of MIS, using either an adeno-associated virus serotype 9 (AAV9) gene therapy vector or recombinant protein, resulted in a complete arrest of folliculogenesis in mice, representing a unique mechanism of contraception that spares the pool of quiescent primordial follicles (ovarian reserve).
Journal ArticleDOI

Suppression of premature termination codons as a therapeutic approach

TL;DR: Current approaches aimed at reducing the efficiency of translation termination at PTCs (referred to as PTC suppression therapy) have the goal of alleviating the phenotypic consequences of a wide range of genetic diseases.